This study is for patients that have a type of brain cancer called Glioblastoma multiforme (GBM). This study will combine two different ways to fight cancer: antibodies and CAR-T cells. Several immune checkpoint antibodies have been examined on various tumors with good outcomes. GBM is known to express increased levels of surface antigens that can be targeted by CAR-T cells. Thus, in this study, the 4SCAR-IgT cells targeting GBM surface antigens will be infused in dose escalation cohorts.